To hear about similar clinical trials, please enter your email below
Trial Title:
Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma
NCT ID:
NCT05595265
Condition:
Nasopharyngeal and Hypopharyngeal Carcinoma
Conditions: Official terms:
Carcinoma
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
immunohistochemical
Description:
Immunohistochemical Evaluation: Corresponding sections of 4µm thickness from each
Formalin-fixed paraffin blocks will be immunohistochemically stained by anti- PD-L1
antibody according to the recommended protocol.
Summary:
Head and neck tumors comprise heterogeneous neoplasms that arise from surface epithelium
of different anatomic subsites in head and neck region such as oral cavity, oropharynx,
larynx and hypopharynx. Nasopharyngeal and hypopharyngeal carcinomas represent 0.26 % of
all cancers in Egypt. Tobacco exposure and alcohol dependence, and infection with
oncogenic viruses such as human Papilloma virus (HPV) are among the risk factors for
development of these tumors. Currently, the main treatment of nasopharyngeal and
hypopharyngeal carcinomas is radio-chemotherapy based in histological type, grade and
stages of the tumors
Tumor infiltrating lymphocytes (TILs) are considered as cornerstone in cancer
immunotherapy and as a biomarker with effectiveness predictive value. The intensity and
quality of immune cells, especially lymphocytes, in tumor microenvironment are strongly
related to the outcome of immune checkpoint blockade therapy .
Criteria for eligibility:
Study pop:
- Patients with nasopharyngeal and hypopharyngeal carcinomas who underwent diagnostic
biopsies.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Patients with nasopharyngeal and hypopharyngeal carcinomas who underwent diagnostic
biopsies.
Exclusion Criteria:
- Patients received chemotherapy or radiotherapy.
- Patients with insufficient clinical data.
- Specimens with extensive necrosis
- Tiny specimens which are insufficient for accurate diagnosis.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Locations:
Facility:
Name:
Sohag University Hospital
Address:
City:
Sohag
Country:
Egypt
Contact:
Last name:
magdy m ameen, professor
Start date:
November 2022
Completion date:
November 2023
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05595265
